Clinical Trials for Liver Cancer

A Phase 1, Open-Label Study of ABSK-011 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with advanced solid tumors for dose escalation and a biomarker-selected expansion in FGF19-overexpressing BCLC B/C hepatocellular carcinoma (Child-Pugh A–B7), after or unsuitable for first-line systemic therapy. Patients receive oral irpagratinib (ABSK-011), a selective covalent FGFR4 inhibitor targeting FGF19–FGFR4 signaling, given QD or BID in 28-day cycles.

ClinicalTrials.gov ID: NCT04906434

Phase II Single Arm Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis (STRIDE in CP-B)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced HCC (BCLC B not eligible for locoregional therapy or BCLC C) and Child-Pugh B7–B8 cirrhosis, ECOG 0–1, no prior systemic therapy, including HBV/HCV with control. Patients receive the STRIDE regimen: a single priming dose of tremelimumab (CTLA-4 inhibitor) plus durvalumab maintenance (PD-L1 inhibitor) given every 4 weeks until progression or toxicity.

ClinicalTrials.gov ID: NCT06526104

Safety and Immunological Effects of Pembrolizumab Plus Ablative Radiotherapy in Patients With Advanced Adrenocortical Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for adolescents and adults with metastatic adrenocortical carcinoma with symptomatic liver metastases and extrahepatic disease, ECOG 0–1, and no prior PD-1/PD-L1/CTLA-4 therapy, evaluating ablative radiotherapy to liver lesions followed by pembrolizumab. Pembrolizumab is an anti–PD-1 monoclonal antibody intended to enhance antitumor T-cell activity, with the RT combination aiming to potentiate systemic immune responses.

ClinicalTrials.gov ID: NCT06066333

A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable, locally advanced/metastatic HCC and Child-Pugh B7–B8 cirrhosis, ECOG 0–2, and no prior systemic therapy receive either atezolizumab plus bevacizumab (anti–PD-L1 + anti-VEGF) or atezolizumab alone, with emphasis on safety/tolerability in this higher-risk population. Excludes high bleeding risk (e.g., recent/active variceal bleeding), significant autoimmune disease, prior checkpoint inhibitors, and TIPS for the combo cohort.

ClinicalTrials.gov ID: NCT06096779

Regorafenib and Yttrium-90 Radioembolization for Treatment of Unresectable Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable HCC (Child-Pugh A–B7), no prior systemic therapy, and suitable anatomy for Y-90 TARE receive combined Y-90 radioembolization (TheraSphere) plus regorafenib, an oral multikinase inhibitor of VEGFR1–3, TIE2, KIT, RET, and RAF. Excludes major extrahepatic disease and significant comorbidities; aims to assess disease control and safety.

ClinicalTrials.gov ID: NCT06902246

REVERT- Liver Cancer: A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, locally advanced or metastatic HCC (Child-Pugh A–B7, ECOG 0–1) receive the oral STAT3 inhibitor TTI-101 as monotherapy after prior systemic therapy, or in combination with pembrolizumab after PD-1/PD-L1 progression, or with atezolizumab plus bevacizumab in the first-line setting. The study evaluates safety and preliminary efficacy, with standard bevacizumab eligibility and exclusion of patients with contraindications to immunotherapy.

ClinicalTrials.gov ID: NCT05440708

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424

PRIME-LRT: PRomoting IMmunotherapy Efficacy With Low-Dose Liver RT

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolls adults with biopsy-proven NSCLC (excluding EGFR/ALK/ROS1/RET-altered tumors) or melanoma with radiographic liver metastases, ECOG 0–2, eligible for standard PD-1/PD-L1 checkpoint inhibitor–based therapy (± chemotherapy and/or CTLA-4 inhibition per routine practice). All patients receive standard systemic therapy plus investigational low-dose liver radiation delivered in the week before cycles 1, 2, and 3 to potentially modulate the hepatic immune microenvironment and enhance checkpoint inhibitor efficacy.

ClinicalTrials.gov ID: NCT07225036

Phase 1, Single-site, Single-arm, Clinical Imaging, and Blood-based Biomarker Trial Utilizing 18F-FSPG PET to Guide Therapy in Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults (≥18) with imaging- or pathology-confirmed hepatocellular carcinoma meeting LI-RADS criteria who are candidates for Y90 radioembolization monotherapy. Patients receive standard Y90, with investigational 18F-FSPG PET/CT (a glutamate analog tracer reflecting system xC−/redox-related amino acid transport activity) plus paired ctDNA blood sampling before and after treatment to assess early prediction/detection of response or resistance versus standard imaging over 12 months.

ClinicalTrials.gov ID: NCT07116486

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with resectable, liver-confined colorectal cancer metastases (≥1 lesion ≥2 cm) scheduled for standard hepatectomy undergo percutaneous implantation of an intratumoral microdevice into a liver metastasis 3–5 days pre-op, with en bloc retrieval at surgery. The device locally releases microdoses of multiple anticancer agents (e.g., FOLFOX/FOLFIRI/FOLFIRINOX components, bevacizumab, doxorubicin, and immunotherapies including botensilimab [Fc-enhanced anti–CTLA-4], balstilimab [anti–PD-1], and AGEN2373) to assess tissue-level drug diffusion and pharmacodynamic response, focusing on procedural safety/feasibility rather than systemic treatment.

ClinicalTrials.gov ID: NCT07193862